A variant erythroferrone disrupts iron homeostasis in SF3B1 -mutated myelodysplastic syndrome

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106 · see citing works

Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization

Nemeth, E., Tuttle, M. S., Powelson, J., Vaughn, M. B., Donovan, A., Ward, D. M., Ganz, T., & Kaplan, J. (2004) · Science · doi:10.1126/science.1104742 · Cited by 4,803 · see citing works

Letter to the editors

Roepstorff, P., & Fohlman, J. (1984) · Journal of Mass Spectrometry · doi:10.1002/bms.1200111109 · Cited by 2,637 · see citing works

Frequent pathway mutations of splicing machinery in myelodysplasia

Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., et al. (2011) · Nature · doi:10.1038/nature10496 · Cited by 2,029 · see citing works

Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein

Nemeth, E., Valore, E. V., Territo, M., Schiller, G., Lichtenstein, A., & Ganz, T. (2003) · Blood · doi:10.1182/blood-2002-10-3235 · Cited by 1,417 · see citing works

Somatic<i>SF3B1</i>Mutation in Myelodysplasia with Ring Sideroblasts

Papaemmanuil, E., Cazzola, M., Boultwood, J., Malcovati, L., Vyas, P., Bowen, D., Pellagatti, A., Wainscoat, J. S., Hellstrom-Lindberg, E., Gambacorti-Passerini, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103283 · Cited by 1,222 · see citing works

The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation

Nicolas, G., Chauvet, C., Viatte, L., Danan, J. L., Bigard, X., Devaux, I., Beaumont, C., Kahn, A., & Vaulont, S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215686 · Cited by 1,214 · see citing works

Identification of erythroferrone as an erythroid regulator of iron metabolism

Kautz, L., Jung, G., Valore, E. V., Rivella, S., Nemeth, E., & Ganz, T. (2014) · Nature Genetics · doi:10.1038/ng.2996 · Cited by 1,127 · see citing works

Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia

Quesada, V., Conde, L., Villamor, N., Ordóñez, G. R., Jares, P., Bassaganyas, L., Ramsay, A. J., Beà, S., Pinyol, M., Martínez‐Trillos, A., et al. (2011) · Nature Genetics · doi:10.1038/ng.1032 · Cited by 987 · see citing works

High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin

Tanno, T., Bhanu, N. V., Oneal, P. A., Goh, S.-H., Staker, P., Lee, Y. T., Moroney, J. W., Reed, C. H., Luban, N. L., Wang, R.-H., et al. (2007) · Nature Medicine · doi:10.1038/nm1629 · Cited by 854 · see citing works

Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease

Weinstein, D. A., Roy, C. N., Fleming, M. D., Loda, M. F., Wolfsdorf, J. I., & Andrews, N. C. (2002) · Blood · doi:10.1182/blood-2002-04-1260 · Cited by 632 · see citing works

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms

Malcovati, L., Papaemmanuil, E., Bowen, D., Boultwood, J., Porta, M. G. D., Pascutto, C., Travaglino, E., Groves, M. J., Godfrey, A. L., Ambaglio, I., et al. (2011) · Blood · doi:10.1182/blood-2011-09-377275 · Cited by 496 · see citing works

Suppression of hepcidin during anemia requires erythropoietic activity

Pak, M., Lopez, M. A., Gabayan, V., Ganz, T., & Rivera, S. (2006) · Blood · doi:10.1182/blood-2006-06-028787 · Cited by 472 · see citing works

Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3′ Splice Site Selection through Use of a Different Branch Point

Darman, R. B., Seiler, M., Agrawal, A. A., Lim, K., Peng, S., Aird, D. R., Bailey, S., Bhavsar, E. B., Chan, B., Colla, S., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.09.053 · Cited by 455 · see citing works

Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis

Suragani, R. N. V. S., Cadena, S. M., Cawley, S. M., Sako, D., Mitchell, D., Li, R., Davies, M. V., Alexander, M. J., Devine, M., Loveday, K. S., et al. (2014) · Nature Medicine · doi:10.1038/nm.3512 · Cited by 452 · see citing works

SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts

Malcovati, L., Karimi, M., Papaemmanuil, E., Ambaglio, I., Jädersten, M., Jansson, M., Elena, C., Gallì, A., Walldin, G., Della Porta, M. G., et al. (2015) · Blood · doi:10.1182/blood-2015-03-633537 · Cited by 434 · see citing works

Global regulation of erythroid gene expression by transcription factor GATA-1

Welch, J. J. (2004) · Blood · doi:10.1182/blood-2004-04-1603 · Cited by 408 · see citing works

Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage

Alsafadi, S., Houy, A., Battistella, A., Popova, T. G., Wassef, M. A., Henry, E., Tirode, F., Constantinou, A., Piperno-Neumann, S., Roman‐Roman, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms10615 · Cited by 385 · see citing works

Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation

Obeng, E. A., Chappell, R. J., Seiler, M., Chen, M. C., Campagna, D. R., Schmidt, P. J., Schneider, R. K., Lord, A. M., Wang, L., Gambe, R. G., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.08.006 · Cited by 380 · see citing works

Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells

Tanno, T., Porayette, P., Sripichai, O., Noh, S.-J., Byrnes, C., Bhupatiraju, A., Lee, Y. T., Goodnough, J. B., Harandi, O., Ganz, T., et al. (2009) · Blood · doi:10.1182/blood-2008-12-195503 · Cited by 352 · see citing works

Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis

Nicolas, G., Viatte, L., Lou, D.-Q., Bennoun, M., Beaumont, C., Kahn, A., Andrews, N. C., & Vaulont, S. (2003) · Nature Genetics · doi:10.1038/ng1150 · Cited by 311 · see citing works

Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study

Platzbecker, U., Germing, U., Götze, K. S., Kiewe, P., Mayer, K., Chromik, J., Radsak, M., Wolff, T., Zhang, X., Laadem, A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30615-0 · Cited by 292 · see citing works

An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia

Dussiot, M., Maciel, T. T., Fricot, A., Chartier, C., Negre, O., Veiga, J., Grapton, D., Paubelle, E., Payen, E., Beuzard, Y., et al. (2014) · Nature Medicine · doi:10.1038/nm.3468 · Cited by 279 · see citing works

Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients

Damm, F., Mylonas, E., Cosson, A., Yoshida, K., Della-Valle, V., Mouly, E., Diop, M. K., Scourzic, L., Shiraishi, Y., Chiba, K., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0104 · Cited by 266 · see citing works

Metabolic function of the CTRP family of hormones

Seldin, M. M., Tan, S. Y., & Wong, G. W. (2013) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-013-9255-7 · Cited by 244 · see citing works

Molecular Architecture of SF3b and Structural Consequences of Its Cancer-Related Mutations

Cretu, C., Schmitzová, J., Ponce-Salvatierra, A., Dybkov, O., Laurentiis, E. I. D., Sharma, K., Will, C. L., Urlaub, H., Lührmann, R., & Peña, V. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.08.036 · Cited by 242 · see citing works

Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations

Pellagatti, A., Armstrong, R. N., Steeples, V., Sharma, E., Repapi, E., Singh, S., Sanchi, A., Radujkovic, A., Horn, P., Dolatshad, H., et al. (2018) · Blood · doi:10.1182/blood-2018-04-843771 · Cited by 240 · see citing works

Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes

Damm, F., Kosmider, O., Gelsi‐Boyer, V., Renneville, A., Carbuccia, N., Hidalgo-Curtis, C., Della-Valle, V., Couronné, L., Scourzic, L., Chesnais, V., et al. (2012) · Blood · doi:10.1182/blood-2011-12-400994 · Cited by 232 · see citing works

Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice

Gardenghi, S., Ramos, P., Marongiu, M. F., Melchiori, L., Breda, L., Guy, E., Muirhead, K., Rao, N., Roy, C. N., Andrews, N. C., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41717 · Cited by 220 · see citing works

Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia

Wang, L., Brooks, A. N., Fan, J., Wan, Y., Gambe, R. G., Li, S., Hergert, S., Yin, S., Freeman, S. S., Levin, J. Z., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.10.005 · Cited by 208 · see citing works

Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin

Ashby, D. R., Gale, D. P., Busbridge, M., Murphy, K. G., Duncan, N. D., Cairns, T. D., Taube, D. H., Bloom, S. R., Tam, F. W. K., Chapman, R., et al. (2010) · Haematologica · doi:10.3324/haematol.2009.013136 · Cited by 191 · cited 1× · see citing works

Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia

Shiozawa, Y., Malcovati, L., Gallì, A., Sato‐Otsubo, A., Kataoka, K., Sato, Y., Watatani, Y., Suzuki, H., Yoshizato, T., Yoshida, K., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06063-x · Cited by 172 · see citing works

Deferasirox Reduces Serum Ferritin and Labile Plasma Iron in RBC Transfusion–Dependent Patients With Myelodysplastic Syndrome

List, A. F., Baer, M. R., Steensma, D. P., Raza, A., Esposito, J., Martinez-Lopez, N., Paley, C. S., Feigert, J. M., & Besa, E. C. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.1222 · Cited by 170 · see citing works

Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes

Gattermann, N., Finelli, C., Porta, M. G. D., Fenaux, P., Stadler, M., Guerci‐Bresler, A., Schmid, M., Taylor, K. F., Vassilieff, D., Habr, D., et al. (2012) · Haematologica · doi:10.3324/haematol.2011.048546 · Cited by 165 · see citing works

Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with β-thalassemia major: a longitudinal study

Pasricha, S., Frazer, D. M., Bowden, D. K., & Anderson, G. J. (2013) · Blood · doi:10.1182/blood-2012-12-471441 · Cited by 154 · see citing works

Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes

Dolatshad, H., Pellagatti, A., Liberante, F. G., Llorian, M., Repapi, E., Steeples, V., Roy, S., Scifo, L., Armstrong, R. N., Shaw, J. M., et al. (2016) · Leukemia · doi:10.1038/leu.2016.149 · Cited by 137 · see citing works

Elevated growth differentiation factor 15 expression in patients with congenital dyserythropoietic anemia type I

Tamary, H., Shalev, H., Perez-Avraham, G., Zoldan, M., Levi, I., Swinkels, D. W., Tanno, T., & Miller, J. L. (2008) · Blood · doi:10.1182/blood-2008-06-165738 · Cited by 135 · see citing works

Hepcidin Levels and Their Determinants in Different Types of Myelodysplastic Syndromes

Santini, V., Girelli, D., Sanna, A., Martinelli, N., Duca, L., Campostrini, N., Cortelezzi, A., Corbella, M., Bosi, A., Reda, G., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023109 · Cited by 133 · see citing works

Immunoassay for human serum erythroferrone

Ganz, T., Jung, G., Naeim, A., Ginzburg, Y., Pakbaz, Z., Walter, P. B., Kautz, L., & Nemeth, E. (2017) · Blood · doi:10.1182/blood-2017-04-777987 · Cited by 125 · see citing works

Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion

Toma, A., Kosmider, O., Chevret, S., Delaunay, J., Stamatoullas, A., Rosé, C., Beyne‐Rauzy, O., Baños, A., Guerci‐Bresler, A., Wickenhauser, S., et al. (2015) · Leukemia · doi:10.1038/leu.2015.296 · Cited by 121 · see citing works

Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes

Tehranchi, R. (2005) · Blood · doi:10.1182/blood-2004-12-4649 · Cited by 104 · see citing works

The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts

Nikpour, M., Scharenberg, C., Liu, A., Conte, S., Karimi, M., Blanco, T. M., Giai, V., Fernández‐Mercado, M., Papaemmanuil, E., Högstrand, K., et al. (2012) · Leukemia · doi:10.1038/leu.2012.298 · Cited by 99 · see citing works

Natural history of idiopathic refractory sideroblastic anemia

Cazzola, M., Barosi, G., Gobbi, P. G., Invernizzi, R., Riccardi, A., & Ascari, E. (1988) · Blood · doi:10.1182/blood.v71.2.305.305 · Cited by 98 · see citing works

A Chemical Genetics Approach for the Functional Assessment of Novel Cancer Genes

Zhou, Q., Derti, A., Ruddy, D. A., Rakiec, D. P., Kao, I., Lira, M., Gibaja, V., Chan, H., Yang, Y., Min, J., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2930 · Cited by 81 · see citing works

SF3B1 mutant MDS-initiating cells may arise from the haematopoietic stem cell compartment

Mian, S. A., Rouault‐Pierre, K., Smith, A., Seidl, T., Pizzitola, I., Kizilors, A., Kulasekararaj, A. G., Bonnet, D. A., & Mufti, G. J. (2015) · Nature Communications · doi:10.1038/ncomms10004 · Cited by 80 · see citing works

SF3B1-initiating mutations in MDS-RSs target lymphomyeloid hematopoietic stem cells

Blanco, T. M., Dimitriou, M., Woll, P. S., Karimi, M., Elvarsdóttir, E. M., Conte, S., Tobiasson, M., Jansson, M., Douagi, I., Moarii, M., et al. (2017) · Blood · doi:10.1182/blood-2017-03-776070 · Cited by 75 · see citing works

Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1

Ambaglio, I., Malcovati, L., Papaemmanuil, E., Laarakkers, C. M., Porta, M. G. D., Gallì, A., Vià, M. D., Bono, E. B., Ubezio, M., Travaglino, E., et al. (2013) · Haematologica · doi:10.3324/haematol.2012.077446 · Cited by 59 · see citing works

Serum iron metabolism and erythropoiesis in patients with myelodysplastic syndrome not receiving RBC transfusions

Cui, R., Gale, R. P., Zhu, G., Xu, Z., Qin, T., Zhang, Y., Huang, G., Li, B., Fang, L., Zhang, H., et al. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.01.016 · Cited by 52 · see citing works

LC-MS/MS method for hepcidin-25 measurement in human and mouse serum: clinical and research implications in iron disorders

Lefèbvre, T., Dessendier, N., Houamel, D., Ialy-Radio, N., Kannengiesser, C., Manceau, H., Beaumont, C., Nicolas, G., Gouya, L., Puy, H., et al. (2015) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2014-1093 · Cited by 50 · see citing works

Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes

de Swart, L., Reiniers, C., Bagguley, T., van Marrewijk, C., Bowen, D., Hellström-Lindberg, E., Tatic, A., Symeonidis, A., Huls, G., Cermak, J., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.171884 · Cited by 48 · see citing works

Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion

Chesnais, V., Renneville, A., Toma, A., Lambert, J., Passet, M., Dumont, F., Chevret, S., Lejeune, J., Raimbault, A., Stamatoullas, A., et al. (2015) · Blood · doi:10.1182/blood-2015-04-640128 · Cited by 42 · see citing works

Reactive oxygen species levels control NF-κB activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic syndromes

Meunier, M., Ancelet, S., Lefebvre, C., Arnaud, J., Garrel, C., Pezet, M., Wang, Y., Faure, P., Szymanski, G., Duployez, N., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22299 · Cited by 36 · see citing works

A common alternative splicing signature is associated with SF3B1 mutations in malignancies from different cell lineages

Gentien, D., Kosmider, O., Nguyen‐Khac, F., Albaud, B., Rapinat, A., Dumont, A. G., Damm, F., Popova, T. G., Marais, R., Fontenay, M., et al. (2014) · Leukemia · doi:10.1038/leu.2014.28 · Cited by 33 · see citing works

Spontaneous and Fas-induced apoptosis of low-grade MDS erythroid precursors involves the endoplasmic reticulum

Gyan, E., Frisan, E., Beyne‐Rauzy, O., Deschemin, J., Pierre‐Eugène, C., Randriamampita, C., Dubart‐Kupperschmitt, A., Garrido, C., Dreyfus, F., Mayeux, P., et al. (2008) · Leukemia · doi:10.1038/leu.2008.172 · Cited by 31 · see citing works

Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes

Chesnais, V., Arcangeli, M.-L., Delette, C., Rousseau, A., Guermouche, H., Lefèvre, C., Bondu, S., Diop, M. K., Cheok, M. H.-C., Chapuis, N., et al. (2016) · Blood · doi:10.1182/blood-2016-03-707745 · Cited by 26 · see citing works

Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes

Park, S., Kosmider, O., Maloisel, F., Drénou, B., Chapuis, N., Lefèbvre, T., Karim, Z., Puy, H., Alary, A., Ducamp, S., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.203158 · Cited by 23 · see citing works

SF3B1-mutated myelodysplastic syndrome with ring sideroblasts harbors more severe iron overload and corresponding over-erythropoiesis

Zhu, Y., Li, X., Chang, C., Xu, F., He, Q., Guo, J., Tao, Y., Liu, Y., Liu, L., & Shi, W. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.02.011 · Cited by 18 · see citing works

The soluble transferrin receptor in dysplastic erythropoiesis in myelodysplastic syndrome

Metzgeroth, G., Rosée, P. G. L., Kühn, C., Schultheis, B. S., Dorn‐Beineke, A., Hehlmann, R., & Hastka, J. (2007) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2007.00863.x · Cited by 10 · see citing works

Characterization of the erythropoiesis in myelodysplasia by means of ferrokinetic studies, in vitro erythroid colony formation and soluble transferrin receptor

Brada, S., de Wolf, J. T., Hendriks, D., Louwes, H., van den Berg, E., & Vellenga, E. (1998) · Leukemia · doi:10.1038/sj.leu.2400961 · Cited by 9 · see citing works

Comprehensive Analysis of Aberrant RNA Splicing in Myelodysplastic Syndromes

Shiozawa, Y., Sato-Otsubo, S., Gallì, A., Yoshida, K., Yoshizato, T., Sato, Y., Kataoka, K., Sanada, M., Shiraishi, Y., Chiba, K., et al. (2014) · Blood · doi:10.1182/blood.v124.21.826.826 · Cited by 7 · see citing works

Iron metabolism and iron disorders revisited in the hepcidin era

Camaschella, C., Nai, A., & Silvestri, L. (2020) · Haematologica · doi:10.3324/haematol.2019.232124 · Cited by 734 · see citing works

Myelodysplastic Syndromes

Cazzola, M. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1904794 · Cited by 496 · see citing works

Alternative splicing and related RNA binding proteins in human health and disease

Tao, Y., Zhang, Q., Wang, H., Yang, X., & Mu, H. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01734-2 · Cited by 342 · see citing works

SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS

Malcovati, L., Stevenson, K. E., Papaemmanuil, E., Neuberg, D. S., Bejar, R. L., Boultwood, J., Bowen, D., Campbell, P. J., Ebert, B. L., Fenaux, P., et al. (2020) · Blood · doi:10.1182/blood.2020004850 · Cited by 298 · see citing works

Hepcidin and Anemia: A Tight Relationship

Pagani, A., Nai, A., Silvestri, L., & Camaschella, C. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.01294 · Cited by 256 · see citing works

Hemochromatosis classification: update and recommendations by the BIOIRON Society

Girelli, D., Busti, F., Brissot, P., Cabantchik, I. Z., Muckenthaler, M. U., & Porto, G. (2021) · Blood · doi:10.1182/blood.2021011338 · Cited by 186 · see citing works

Erythroferrone structure, function, and physiology: Iron homeostasis and beyond

Srole, D. N., & Ganz, T. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30247 · Cited by 155 · see citing works

Ineffective erythropoiesis and its treatment

Cazzola, M. (2021) · Blood · doi:10.1182/blood.2021011045 · Cited by 98 · see citing works

The Clinical Significance of Iron Overload and Iron Metabolism in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Weber, S., Parmon, A., Kurrle, N., Schnütgen, F., & Serve, H. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.627662 · Cited by 86 · see citing works

Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms

Taylor, J., Mi, X., North, K., Binder, M., Penson, A. V., Lasho, T. L., Knorr, K. L. B., Haddadin, M., Liu, B., Pangallo, J., et al. (2020) · Blood · doi:10.1182/blood.2020006868 · Cited by 60 · see citing works

SF3B1 mutant-induced missplicing of MAP3K7 causes anemia in myelodysplastic syndromes

Lieu, Y. K., Liu, Z., Ali, A. M., Wei, X., Penson, A., Zhang, J., An, X., Rabadán, R., Raza, A., Manley, J. L., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2111703119 · Cited by 59 · see citing works

From Iron Chelation to Overload as a Therapeutic Strategy to Induce Ferroptosis in Leukemic Cells

Grignano, É., Birsen, R., Chapuis, N., & Bouscary, D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.586530 · Cited by 54 · see citing works

Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasms

Zhang, Y., Wu, J., Qin, T., Xu, Z., Qu, S., Pan, L., Li, B., Wang, H., Zhang, P., Yan, X., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01718-7 · Cited by 52 · see citing works

Controversies on the Consequences of Iron Overload and Chelation in MDS

Vinchi, F., Hell, S., & Platzbecker, U. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000357 · Cited by 42 · see citing works

The hepatokine FGL1 regulates hepcidin and iron metabolism during anemia in mice by antagonizing BMP signaling

Sardo, U., Perrier, P., Cormier, K., Sotin, M., Personnaz, J., Medjbeur, T., Desquesnes, A., Cannizzo, L., Ruíz-Martínez, M., Thevenin, J., et al. (2024) · Blood · doi:10.1182/blood.2023022724 · Cited by 34 · see citing works

Role of reactive oxygen species in myelodysplastic syndromes

Jing, Q., Zhou, C., Zhang, J., Zhang, P., Wu, Y., Zhou, J., Tong, X., Li, Y., Du, J., & Wang, Y. (2024) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-024-00570-0 · Cited by 33 · see citing works

Vitamin B5 and succinyl-CoA improve ineffective erythropoiesis in SF3B1 -mutated myelodysplasia

Mian, S. A., Philippe, C., Maniati, E., Protopapa, P., Bergot, T., Piganeau, M., Nemkov, T. G., Bella, D. D., Morales, V., Finch, A. J., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abn5135 · Cited by 28 · see citing works

SF3B1 mutations in myelodysplastic syndromes: A potential therapeutic target for modulating the entire disease process

Jiang, M., Chen, M., Liu, Q., Jin, Z., Yang, X., & Zhang, W. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1116438 · Cited by 29 · see citing works

The Role of Iron in Benign and Malignant Hematopoiesis

Sinha, S., Pereira-Reis, J., Guerra, A., Rivella, S., & Duarte, D. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2020.8155 · Cited by 29 · see citing works

Iron-mediated tissue damage in acquired ineffective erythropoiesis disease: It’s more a matter of burden or more of exposure to toxic iron form?

Pilo, F., Cilloni, D., Porta, M. G. D., Forni, G. L., Piperno, A., Santini, V., & Angelucci, E. (2022) · Leukemia Research · doi:10.1016/j.leukres.2022.106792 · Cited by 27 · see citing works

Hypoferremia of inflammation: Innate host defense against infections

Ganz, T., & Nemeth, E. (2023) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2023.102777 · Cited by 27 · see citing works

Iron Mining for Erythropoiesis

Correnti, M., Gammella, E., Cairo, G., & Recalcati, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105341 · Cited by 27 · see citing works

Erythroferrone exacerbates iron overload and ineffective extramedullary erythropoiesis in a mouse model of β-thalassemia

Olivera, J. D., Zhang, V., Nemeth, E., & Ganz, T. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009307 · Cited by 23 · see citing works

USH2A Mutation is Associated With Tumor Mutation Burden and Antitumor Immunity in Patients With Colon Adenocarcinoma

Sun, Y., Li, L., Yao, W., Liu, X., Yang, Y., Ma, B., & Xue, D. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.762160 · Cited by 21 · see citing works

Exploring the mechanistic link between SF3B1 mutation and ring sideroblast formation in myelodysplastic syndrome

Ochi, T., Fujiwara, T., Ono, K., Suzuki, C., Nikaido, M., Inoue, D., Kato, H., Onodera, K., Ichikawa, S., Fukuhara, N., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-18921-2 · Cited by 22 · see citing works

Mutation in SF3B1 gene promotes formation of polyploid giant cells in Leukemia cells

Mukherjee, S., Ali, A. M., Murty, V. V. V. S., & Raza, A. (2022) · Medical Oncology · doi:10.1007/s12032-022-01652-9 · Cited by 21 · see citing works

SF3B1 mutant myelodysplastic syndrome: Recent advances

Pellagatti, A., & Boultwood, J. (2020) · Advances in Biological Regulation · doi:10.1016/j.jbior.2020.100776 · Cited by 20 · see citing works

Causes of Clonal Hematopoiesis: a Review

Joo, L., Bradley, C. C., Lin, S. H., Scheet, P. A., & Nead, K. T. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01362-z · Cited by 21 · see citing works

Splicing factor mutations in the myelodysplastic syndromes: Role of key aberrantly spliced genes in disease pathophysiology and treatment

Pellagatti, A., & Boultwood, J. (2022) · Advances in Biological Regulation · doi:10.1016/j.jbior.2022.100920 · Cited by 19 · see citing works

Accelerated DNA replication fork speed due to loss of R-loops in myelodysplastic syndromes with SF3B1 mutation

Rombaut, D., Lefèvre, C., Rached, T., Bondu, S., Letessier, A., Mangione, R. M., Farhat, B., Lesieur, A., Castillo-Guzman, D., Boussaid, I., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46547-7 · Cited by 21 · see citing works

Patient-specific MDS-RS iPSCs define the mis-spliced transcript repertoire and chromatin landscape of SF3B1-mutant HSPCs

Asimomitis, G., Deslauriers, A. G., Kotini, A. G., Bernard, E., Esposito, D., Olszewska, M., Spyrou, N., Ossa, J. A., Blanco, T. M., Koche, R. P., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006325 · Cited by 17 · see citing works

Emerging Pathogenetic Mechanisms and New Drugs for Anemia in Myelofibrosis and Myelodysplastic Syndromes

Gangat, N., & Tefferi, A. (2025) · American Journal of Hematology · doi:10.1002/ajh.27659 · Cited by 17 · see citing works

Mis-splicing of Mitotic Regulators Sensitizes SF3B1-Mutated Human HSCs to CHK1 Inhibition

Sarchi, M., Clough, C. A., Crosse, E. I., Kim, J., Galvis, L. D. B., Aydinyan, N., Wellington, R., Yang, F., Gallì, A., Creamer, J. P., et al. (2024) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0230 · Cited by 17 · see citing works

Molecular Mechanisms of Iron Metabolism and Overload

Tayal, A., Kaur, J., Sadeghi, P., & Maitta, R. W. (2025) · Biomedicines · doi:10.3390/biomedicines13092067 · Cited by 21 · see citing works

Erythroferrone in focus: emerging perspectives in iron metabolism and hematopathologies

Babar, S., & Saboor, M. (2024) · Blood Science · doi:10.1097/bs9.0000000000000198 · Cited by 17 · see citing works

Chromatin-Spliceosome Mutations in Acute Myeloid Leukemia

Ochi, Y., & Ogawa, S. (2021) · Cancers · doi:10.3390/cancers13061232 · Cited by 16 · see citing works

SF3B1: from core splicing factor to oncogenic driver

Bak‐Gordon, P., & Manley, J. L. (2025) · RNA · doi:10.1261/rna.080368.124 · Cited by 15 · see citing works

Mutant SF3B1 promotes malignancy in PDAC

Simmler, P., Ioannidi, E. I., Mengis, T., Marquart, K. F., Asawa, S., Lehmann, K.-V., Kahles, A., Thomas, T. M., Schwerdel, C., Aceto, N., et al. (2023) · eLife · doi:10.7554/elife.80683 · Cited by 15 · see citing works

Human Cancer-Associated Mutations of SF3B1 Lead to a Splicing Modification of Its Own RNA

Bergot, T., Lippert, É., Douet‐Guilbert, N., Commet, S., Corcos, L., & Bernard, D. G. (2020) · Cancers · doi:10.3390/cancers12030652 · Cited by 15 · see citing works

Erythroid Differentiation Enhances RNA Mis-Splicing in SF3B1 -Mutant Myelodysplastic Syndromes with Ring Sideroblasts

Moura, P. L., Blanco, T. M., Hofman, I. J., Todisco, G., Kretzschmar, W. W., Björklund, A.-C., Creignou, M., Hagemann-Jensen, M., Ziegenhain, C., Granados, D. C., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-3038 · Cited by 14 · see citing works

Protein Modifications Critical for Myonectin/Erythroferrone Secretion and Oligomer Assembly

Stewart, A. N., Little, H. C., Clark, D. J., Zhang, H., & Wong, G. W. (2020) · Biochemistry · doi:10.1021/acs.biochem.0c00461 · Cited by 14 · see citing works

The E592K variant of SF3B1 creates unique RNA missplicing and associates with high-risk MDS without ring sideroblasts

Choi, I. Y., Ling, J. P., Zhang, J., Helmenstine, E., Walter, W., Tsakiroglou, P., Bergman, R. E., Philippe, C., Manley, J. L., Rouault‐Pierre, K., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023011260 · Cited by 10 · see citing works

High erythroferrone expression in CD71+ erythroid progenitors predicts superior survival in myelodysplastic syndromes

Riabov, V., Mossner, M., Stöhr, A., Jann, J.-C., Streuer, A., Schmitt, N., Knaflic, A., Nowak, V., Weimer, N., Obländer, J., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17314 · Cited by 11 · see citing works

The Role of Hepcidin in Myelodysplastic Syndromes (MDS): A Systematic Review of Observational Studies

Słomka, A., Pokrzywa, A., Strzała, D., Kubiaczyk, M., Wesolowska, O., Denkiewicz, K., & Styczyński, J. (2024) · Cancers · doi:10.3390/cancers16020332 · Cited by 10 · see citing works

Prognostic Factors and Clinical Considerations for Iron Chelation Therapy in Myelodysplastic Syndrome Patients

Parisi, S., & Finelli, C. (2021) · Journal of Blood Medicine · doi:10.2147/jbm.s287876 · Cited by 10 · see citing works

Fibrinogen‐like 1: A hepatokine linking liver physiology to hematology

Personnaz, J., Guillou, H., & Kautz, L. (2024) · HemaSphere · doi:10.1002/hem3.115 · Cited by 8 · see citing works

EnvIRONmental Aspects in Myelodysplastic Syndrome

Petzer, V., Theurl, I., Weiß, G., & Wolf, D. G. F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105202 · Cited by 10 · see citing works

Cytogenetic and Genetic Abnormalities with Diagnostic Value in Myelodysplastic Syndromes (MDS): Focus on the Pre-Messenger RNA Splicing Process

Douet‐Guilbert, N., Soubise, B., Bernard, D. G., & Troadec, M. (2022) · Diagnostics · doi:10.3390/diagnostics12071658 · Cited by 10 · see citing works

Erythropoiesis in lower-risk myelodysplastic syndromes and beta-thalassemia

Cappellini, M. D., Taher, A. T., Verma, A. K., Shah, F., & Hermine, O. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.101039 · Cited by 6 · see citing works

Distinct routes of clonal progression in SF3B1-mutant myelodysplastic syndromes

Sarchi, M., Clough, C. A., Gallì, A., Picone, C., Ferrari, B., Crosse, E. I., Galvis, L. D. B., Fiducioso, C., Aydinyan, N., Creamer, J. P., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024014965 · Cited by 7 · see citing works

Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions

Bidikian, A., Bewersdorf, J. P., Shallis, R. M., Getz, T. M., Stempel, J. M., Kewan, T. Z., Stahl, M. F., & Zeidan, A. M. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2414071 · Cited by 6 · see citing works

Pathophysiology of Myelodysplastic Syndromes

Fontenay, M., Farhat, B., & Boussaid, I. (2021) · Hemato · doi:10.3390/hemato2030030 · Cited by 6 · see citing works

Differentiating iron-loading anemias using a newly developed and analytically validated ELISA for human serum erythroferrone

Diepeveen, L. E., Roelofs, R., Grebenchtchikov, N. I., van Swelm, R. P. L., Kautz, L., & Swinkels, D. W. (2021) · PLoS ONE · doi:10.1371/journal.pone.0254851 · Cited by 6 · see citing works

Rbm38 deficiency impairs erythroid heme biosynthesis and induces porphyria via reduced ferrochelatase expression

Xie, X., Zou, A., Zhang, L., Ma, X., He, Y., Liu, H., Lu, Y., Yang, Y., Ouyang, J., Liu, K., et al. (2025) · Blood · doi:10.1182/blood.2025028783 · Cited by 5 · see citing works

Dynamics of Erythroferrone Response to Erythropoietin in Rats

Xu, P., Wong, R. S. M., Krzyżański, W., & Yan, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.876573 · Cited by 5 · see citing works

Megaloblastic anemia-related iron overload and erythroid regulators: a case report

Vallet, N., Delaye, J.-B., Ropert, M., Foucault, A., Ravalet, N., Deriaz, S., Chalopin, T., Blasco, H., Maillot, F., Hérault, O., et al. (2021) · Journal of Medical Case Reports · doi:10.1186/s13256-021-03065-0 · Cited by 5 · see citing works

Myelodysplastic Neoplasms (MDS): Pathogenesis and Therapeutic Prospects

Li, X., Zou, C., Xiang, X., Zhao, L., Chen, M., Yang, C., & Wu, Y. (2025) · Biomolecules · doi:10.3390/biom15060761 · Cited by 4 · see citing works

[Expression of iron-regulating erythroid factors in different types of erythropoiesis disorders].

Liu, X., Hu, J. Y., Hu, X., Li, X. X., Guan, D., Liu, J. Q., Zhang, Y. L., & Zhang, F. K. (2021) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2021.01.010 · Cited by 4 · see citing works

Current Therapeutic Landscape in Lower Risk Myelodysplastic Syndromes

Wang, C., & Sallman, D. A. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01062-7 · Cited by 4 · see citing works

Low‐risk MDS—A spotlight on precision medicine for SF3B1‐mutated patients

Burke, S., Chowdhury, O., & Rouault‐Pierre, K. (2025) · HemaSphere · doi:10.1002/hem3.70103 · Cited by 3 · see citing works

MDS/MPN-RS-T justified inclusion as a unique disease entity?

Bravo, G. M., & Garcia‐Manero, G. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101147 · Cited by 3 · see citing works

Novel Insights and Future Perspective in Iron Metabolism and Anemia

Andolfo, I., & Russo, R. (2022) · Metabolites · doi:10.3390/metabo12020138 · Cited by 3 · see citing works

In Silico Pan-Cancer Analysis Reveals Prognostic Role of the Erythroferrone (ERFE) Gene in Human Malignancies

Xu, Q., Altrock, E., Schmitt, N., Streuer, A., Rapp, F., Nowak, V., Obländer, J., Weimer, N., Palme, I., Göl, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021725 · Cited by 3 · see citing works

Transfusion avoidance in myelodysplastic neoplasms

Griffiths, E. A. (2023) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000794 · Cited by 3 · see citing works

Metabolic dysregulation in myelodysplastic neoplasm: impact on pathogenesis and potential therapeutic targets

Zhou, H., Xiang, W., Zhou, G., Rodrigues‐Lima, F., Guidez, F., & Wang, L. (2024) · Medical Oncology · doi:10.1007/s12032-024-02575-3 · Cited by 3 · see citing works

Aberrant splicing of MBD1 reshapes the epigenome to drive convergent myeloerythroid defects in MDS

Chen, H. T., Joshi, P., Cathelin, S., Jahangiri, S., Adeel, S. A., Xu, J., Tsao, E., Mo, Y., Kealy, D., Dowle, A., et al. (2026) · Blood · doi:10.1182/blood.2025030731 · Cited by 2 · see citing works

Understanding iron homeostasis in MDS: the role of erythroferrone

Abba, M. L., Riabov, V., Nowak, D., Hofmann, W., & Boch, T. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1404817 · Cited by 3 · see citing works

Iron Overload, Oxidative Stress, and Somatic Mutations in MDS : What Is the Association?

Leitch, H. A. (2025) · European Journal Of Haematology · doi:10.1111/ejh.14385 · Cited by 2 · see citing works

ERYTHROFERRONE AS A NEW BIOMARKER ASSOCIATED WITH ANEMIA IN IRAQI PATIENTS WITH CKD

Sharba, I. R., Aljabery, H. A., & Al-Khakani, M. F. (2021) · PERIÓDICO TCHÊ QUÍMICA · doi:10.52571/ptq.v18.n37.2021.09_sharba_pgs_135_148.pdf · Cited by 2 · see citing works

The hepatokine FGL1 regulates hepcidin and iron metabolism during the recovery from hemorrhage-induced anemia in micePreprint

Sardo, U., Perrier, P., Cormier, K., Sotin, M., Desquesnes, A., Cannizzo, L., Ruíz-Martínez, M., Thevenin, J., Billoré, B., Jung, G., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.06.535920 · Cited by 2 · see citing works

Iron-Loading Anemias

Levy, M., & Ginzburg, Y. Z. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-92033-2_11 · Cited by 1 · see citing works

Molecular Insights into the Pathophysiology of Dysregulated Erythropoiesis: The Crucial Role of Iron Homeostasis

Fujiwara, T., & Harigae, H. (2025) · Molecular and Cellular Biology · doi:10.1080/10985549.2025.2553648 · Cited by 1 · see citing works

Identification of key genes in cuproptosis during acute kidney injury through weighted gene co-expression network analysis

Gao, X., Liu, X., Liao, H., & Li, R. (2025) · Medicine · doi:10.1097/md.0000000000044592 · Cited by 1 · see citing works

Physiopathologie des syndromes myélodysplasiques

Fontenay, M., Boussaid, I., & Chapuis, N. (2023) · Bulletin du Cancer · doi:10.1016/j.bulcan.2023.02.026 · Cited by 1 · see citing works

A deep dive into future therapies for microcytic anemias and clinical considerations

Rodrigues, F., Coman, T., Fouquet, G., Côté, F., Courtois, G., Maciel, T. T., & Hermine, O. (2023) · Expert Review of Hematology · doi:10.1080/17474086.2023.2206556 · Cited by 1 · see citing works

CDK8 is a critical effector of cell fate dysregulation in SF3B1 -mutant MDSPreprint

Bonner, E. A., Hsueh, T., Song, A., Galvis, L. B., Arriaga-Gomez, E. A., Venkataraman, R., Sinha, S., Nguyen, E., Ferrell, P. B., Welner, R. S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.14.670174 · Cited by 1 · see citing works

RNA splicing factor mutations drive myeloid neoplasm oncogenesis through protein complex poisoningPreprint

Moura, P. L., Branca, R. M., Kaminskiy, Y., Siavelis, I., Shrung, K. R., Hofmann, S., Perraki, C. M., Argyriou, A., Fazeli, S., Nakagawa, M. M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.29.754980 · Cited by 1 · see citing works

Modelling Ineffective Erythropoiesis in Myelodysplastic Syndromes with Ring Sideroblasts

Elvarsdóttir, E. M. (2019) · Figshare · doi:10.13140/rg.2.2.13726.28485

Anemia

Luzzatto, L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00143-2 · Cited by 2 · see citing works

Research progress of iron metabolism and ferroptosis in myeloid neoplasms

Yudi, W. A. N. G., Feng, W., Wang, F., & Min, J. (2024) · Journal of Zhejiang University (Medical Sciences) · doi:10.3724/zdxbyxb-2024-0211

Le rôle de l'érythroferrone dans la régulation du métabolisme du fer

Sardo, U. (2020) · theses.fr (ABES) · doi:10.70675/d03e67aczc44bz4af9z8fa1zef080668f44f

Modeling Chronic Myelomonocytic Leukemia with the Aim of Identifying Novel Therapeutic Targets

Alawieh, D. (2025) · theses.fr (ABES) · doi:10.70675/c7daf13fz397fz4894zbafezd95092b27414

Transfusion-Independent iron overload in SF3B1-mutant myelodysplastic syndrome case report

Zala, A. D., Claudiani, S., & Deplano, S. (2026) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2026.2707444

The SF3b complex in cancer: structural basis, molecular mechanisms, and therapeutic opportunities

Li, S., Shang, L., Yang, J., Huang, Y., Liu, W., Xie, Y., Dong, Z., Jiang, Y., & Liu, K. (2026) · Blood Advances · doi:10.1182/bloodadvances.2026020106

Proteomics of steady-state and culture-derived human erythropoiesis reveals the dynamics of erythroid stressPreprint

Perraki, C. M., Shrung, K. R., Fazeli, S., Kaminskiy, Y., Björklund, A.-C., Barbosa, I., Widfeldt, M. H., Lehtiö, J., Hellström‐Lindberg, E., Blanco, T. M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.13.758834

Gene Expression of the Erythroid Regulator Erythroferrone (ERFE) is Highly Deregulated in CD71+ Erythroprogenitor Cells of Patients with Myelodysplastic Syndromes and Demonstrates Prognostic Relevance

Mossner, M., Stöhr, A., Nolte, F., Jann, J.-C., Fey, S., Nowak, V., Obländer, J., Pressler, J., Baldus, C. D., Schulze, T. J., et al. (2014) · Blood · doi:10.1182/blood.v124.21.4620.4620 · Cited by 3 · see citing works

Erythroferrone (ERFE) Is Selectively Expressed in Human CD71+ Erythroprogenitor Cells and Deregulated Overexpression Is Associated with a Favorable Outcome in Low Risk Myelodysplastic Syndrome (MDS)

Mossner, M., Stöhr, A., Jann, J.-C., Nolte, F., Nowak, V., Oblaender, J., Pressler, J., Xanthopoulos, C., Palme, I., Baldus, C. D., et al. (2015) · Blood · doi:10.1182/blood.v126.23.2859.2859 · Cited by 1 · see citing works

High erythroferrone expression in CD71+ erythroid progenitors predicts superior survival in myelodysplastic syndromes

Riabov, V., Mossner, M., Stöhr, A., Jann, J.-C., Streuer, A., Schmitt, N., Knaflic, A., Nowak, V., Weimer, N., Obländer, J., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17314 · Cited by 11 · see citing works

Understanding iron homeostasis in MDS: the role of erythroferrone

Abba, M. L., Riabov, V., Nowak, D., Hofmann, W., & Boch, T. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1404817 · Cited by 3 · see citing works

MDS-1077: Myelodysplastic Syndrome With SF3B1 Mutation Hidden Behind Anemia of Chronic Kidney Disease: A Diagnostic Odyssey in a Transfusion-Dependent Patient

Karnan, N., & Rao, N. L. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/s2152-2650(26)02262-7